NASDAQ:OXFD', 'Oxford Immunotec Global PLC', 'http://kldaily.com/kl-logo.png');

Oxford Immunotec Global Plc (OXFD) Share Price Rose While New Leaf Venture Partners LLC Cut Its Holding

December 10, 2017 - By Lynda A. Deweese

Investors sentiment decreased to 1.27 in Q2 2017. Its down 0.56, from 1.83 in 2017Q1. It fall, as 10 investors sold OXFD shares while 20 reduced holdings. 8 funds opened positions while 30 raised stakes. 19.91 million shares or 1.07% more from 19.70 million shares in 2017Q1 were reported. Spark Invest Mngmt Limited Liability Com holds 0.16% of its portfolio in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 150,500 shares. 11,458 are owned by Bancshares Of Montreal Can. Fosun Intl invested in 237,783 shares. 524,509 are held by First Light Asset Limited Liability Company. Axa invested in 894,388 shares or 0.07% of the stock. Northwestern Mutual Wealth Mngmt owns 193 shares. Goldman Sachs Grp reported 33,223 shares. Parkwood Ltd Liability Company has invested 0.03% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Moreover, Tiverton Asset Management Ltd has 0.18% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 196,950 shares. New York-based Amer Group has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Morgan Stanley reported 24,182 shares. Wells Fargo And Communication Mn holds 0% or 29,485 shares. Vanguard Grp Incorporated Incorporated invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Legal And General Grp Public Limited Com invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Polar Cap Llp, United Kingdom-based fund reported 2.10 million shares.

Since June 15, 2017, it had 0 buys, and 1 sale for $61,305 activity.

Robert Boucai decreased its stake in Oxford Immunotec Global Plc (OXFD) by 17.35% based on its latest 2017Q2 regulatory filing with the SEC. New Leaf Venture Partners Llc sold 200,000 shares as the company’s stock rose 4.03% with the market. The hedge fund run by Robert Boucai held 952,497 shares of the in vitro & in vivo diagnostic substances company at the end of 2017Q2, valued at $16.02 million, down from 1.15 million at the end of the previous reported quarter. New Leaf Venture Partners Llc who had been investing in Oxford Immunotec Global Plc for a number of months, seems to be less bullish one the $349.68M market cap company. The stock decreased 2.08% or $0.29 during the last trading session, reaching $13.63. About 54,642 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 54.26% since December 10, 2016 and is uptrending. It has outperformed by 37.56% the S&P500.

Analysts await Oxford Immunotec Global PLC (NASDAQ:OXFD) to report earnings on February, 27. They expect $-0.34 EPS, down 54.55 % or $0.12 from last year’s $-0.22 per share. After $-0.24 actual EPS reported by Oxford Immunotec Global PLC for the previous quarter, Wall Street now forecasts 41.67 % negative EPS growth.

More notable recent Oxford Immunotec Global PLC (NASDAQ:OXFD) news were published by: Globenewswire.com which released: “Oxford Immunotec Appoints Stefan Linn as Chief Operating Officer” on August 30, 2017, also Seekingalpha.com with their article: “Oxford Immunotec Global PLC (OXFD) CEO Peter Wrighton-Smith on Q1 2017 Results …” published on May 02, 2017, Globenewswire.com published: “Oxford Immunotec Appoints Richard Wenstrup, MD, as Chief Medical Officer” on July 24, 2017. More interesting news about Oxford Immunotec Global PLC (NASDAQ:OXFD) were released by: Globenewswire.com and their article: “Oxford Immunotec Global PLC Announces Agreement to Sell 2500000 Ordinary Shares” published on August 14, 2017 as well as Globenewswire.com‘s news article titled: “Oxford Immunotec Announces Update in Patent Infringement Litigation” with publication date: September 27, 2017.

Oxford Immunotec Global PLC (NASDAQ:OXFD) Ratings Coverage

Among 4 analysts covering Oxford Immunotec (NASDAQ:OXFD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oxford Immunotec had 8 analyst reports since July 19, 2017 according to SRatingsIntel. The rating was maintained by Robert W. Baird on Tuesday, October 31 with “Buy”. Cowen & Co maintained it with “Buy” rating and $19.0 target in Tuesday, October 31 report. The firm has “Buy” rating by Cowen & Co given on Wednesday, July 19. The stock has “Buy” rating by Robert W. Baird on Thursday, October 19. The firm has “Buy” rating by BTIG Research given on Thursday, September 28. On Wednesday, September 27 the stock rating was maintained by Cowen & Co with “Buy”. The stock of Oxford Immunotec Global PLC (NASDAQ:OXFD) earned “Buy” rating by Cowen & Co on Wednesday, August 16.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.